Abstract | Background: Methods: We retrospective reviewed 72 eyes from 44 treatment-naïve patients who were treated with intravitreal anti- VEGF for DME. OCT scans prior to anti- VEGF were evaluated for serous retinal detachment (SRD), size of outer nuclear layer cystoid changes, diffuse retinal thickening, integrity of the inner segment-outer segment (IS-OS) junction, quantity and location of hyperreflective foci, vitreomacular interface abnormalities, and epiretinal membrane (ERM). The Baseline best-corrected visual acuity (BCVA) and central macular thickness was recorded at baseline and 4 months after treatment with anti- VEGF. The main outcome measure was the correlation between spectral-domain OCT measurements and BCVA response at baseline and after anti- VEGF treatment (mean change from baseline; ≥ 10 Early Treatment Diabetic Retinopathy Study letters in BCVA). Results: Partially continuous IS-OS layers (partially vs. completely continuous: β, -0.138; Wald chi-square, 16.392; P<0.001) was predictor of better response to anti- VEGF treatment. In contrast, ERM (present vs. absent ERM: β, 0.215; Wald chi-square, 5.921; P=0.015) and vitreomacular traction (vitreomacular traction vs. posterior vitreous detachment: β=0.259; Wald chi-square=5.938; P=0.015) were the predictors of poor response. The improvement of BCVA trended toward the OCT predictive value of central macular thickness reduction; however, this was not significant. Conclusion: Partially continuous IS-OS layers is predictive of better response to anti- VEGF therapy in DME. Meanwhile, ERM is a significant predictor of poor response.
|
Authors | Tsung-Cheng Hsieh, Guang-Hong Deng, Yung-Ching Chang, Fang-Ling Chang, Ming-Shan He |
Journal | Frontiers in endocrinology
(Front Endocrinol (Lausanne))
Vol. 14
Pg. 1108097
( 2023)
ISSN: 1664-2392 [Print] Switzerland |
PMID | 37265702
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Hsieh, Deng, Chang, Chang and He. |
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
|
Topics |
- Humans
- Macular Edema
(diagnostic imaging, drug therapy)
- Diabetic Retinopathy
(diagnostic imaging, drug therapy)
- Angiogenesis Inhibitors
(therapeutic use)
- Retrospective Studies
- Vascular Endothelial Growth Factor A
- Diabetes Mellitus
|